CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. The Influences of Adherence to Tamoxifen and CYP2D6 Pharmacogenetics on Plasma Concentrations of the Active Metabolite (Z)-Endoxifen in Breast Cancer.Clinical and translational science · 2020
   Observational
2. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.Journal of neural transmission (Vienna, Austria : 1996) · 2019
   Article
3. Association of CYP2D6*10 (c.100C>T) polymorphisms with clinical outcome of breast cancer after tamoxifen adjuvant endocrine therapy in Chinese population.American journal of translational research · 2016
   Article
4. Endocrine resistance in breast cancer--An overview and update.Molecular and cellular endocrinology · 2015
   Review
5. Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer.The pharmacogenomics journal · 2015
   Observational
6. CYP2D6 genotyping and tamoxifen in the treatment of post-menopausal breast cancer.British journal of clinical pharmacology · 2014
   Article
7. Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.Journal of the National Cancer Institute · 2014
   Article
8. Genomic medicine, precision medicine, personalized medicine: what's in a name?Clinical pharmacology and therapeutics · 2013
   Article
9. Clinical Application of Pharmacogenetics: Where are We Now?EJIFCC · 2013
   Article

Corrections and comments

• Commented on by
  CYP2D6 genotype and tamoxifen activity: understanding interstudy variability in methodological quality.2013

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as